Analysts Offer Insights on Healthcare Companies: Lion Biotechnologies (NASDAQ: LBIO) and Regeneron (NASDAQ: REGN)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lion Biotechnologies (NASDAQ: LBIO) and Regeneron (NASDAQ: REGN).

Lion Biotechnologies (NASDAQ: LBIO)

In a report released today, Boris Peaker from Cowen & Co. reiterated a Buy rating on Lion Biotechnologies (NASDAQ: LBIO). The company’s shares opened today at $5.80.

Peaker commented:

“LBIO reported 3Q financials and provided a pipeline update.”

According to TipRanks.com, Peaker is a 3-star analyst with an average return of 1.7% and a 34.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Lion Biotechnologies has an analyst consensus of Strong Buy.

Regeneron (NASDAQ: REGN)

Canaccord Genuity analyst John Newman reiterated a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $450. The company’s shares opened today at $325.62, close to its 52-week low of $325.35.

According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -20.5% and a 23.4% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $526, representing a 61.5% upside.

In a report issued on October 28, Piper Jaffray also maintained a Hold rating on the stock with a $447 price target.